ities is that they are glucose-dependent: under hyperglycemic conditions (ϳ300 mg/dl glucose concentration) islet blood cells move faster, and under hypoglycemic conditions (ϳ50 mg/dl glucose concentration) they move more slowly (25, 42) . In contrast, blood cell velocities in the exocrine pancreas appear to be independent of glucose levels. The underlying mechanisms of this differential control of islet circulation are currently unknown.
In isolated islets, oscillating calcium waves are observed in response to an increase in glucose concentration (5, 36) . These waves are directly connected to the pulsatile release of insulin from the islets (16) . Furthermore, coordination of the waves is dependent upon the presence of Cx36 gap junction channels between the ␤-cells in both mouse (5, 47, 49) and human (28, 38, 50) islets. In islets lacking Cx36 gap junctions (Cx36 Ϫ/Ϫ ), glucose-stimulated calcium oscillations are no longer coordinated across the islet ␤-cells (5) . In both islets and mice that lack Cx36, a reduced peak of first-phase insulin secretion and a reduced amplitude of second-phase oscillations are observed (18) , and these correlate with impaired glucose tolerance. This is similar to the effects observed in type 2 diabetes, where first-phase insulin secretion (40, 45) and the amplitude of second-phase oscillations (39, 46) are both reduced. We hypothesize that the coordinated glucose-stimulated electrical activity throughout the islet couples to the vasculature and leads to increased islet blood cell flow during hyperglycemia. This hypothesis implies that glucose-dependent changes in blood cell velocities should be greatly reduced in animals lacking ␤-cell gap junctions (Cx36 Ϫ/Ϫ mice). To test this hypothesis, we measured in vivo islet and exocrine tissue blood cell velocities in wild-type, Cx36 ϩ/Ϫ , and Cx36 Ϫ/Ϫ mice. These data show that islet blood cell velocities do not increase with glucose when ␤-cell gap junction channels are reduced or absent, which correlates with reduced insulin release into the bloodstream upon elevated glucose in these animals.
MATERIALS AND METHODS
Animals. Experiments involving mice were approved by and performed according to the guidelines of the Vanderbilt University Institutional Animal Care and Use Committee. The experimental procedures referred to in this article involving pancreas exteriorization and in vivo fluorescence imaging are similar to those discussed previously (42) . The mouse insulin I promoter-green fluorescent protein (GFP) transgenic mice were courtesy of Hara et al. from the University of Chicago (17) . These mice were bred with Cx36 Ϫ/Ϫ mice (12) to obtain Cx36/GFP transgenic mice. Subsequently, Cx36
Ϫ/Ϫ / GFP, Cx36 ϩ/Ϫ /GFP, and Cx36 ϩ/ϩ /GFP mice were obtained by using breeding pairs of Cx36 ϩ/Ϫ /GFP mice. All mice were on a C57BL/6J inbred strain background. Genotyping was done using the upstream intron Cx36 primer, TGCATTTGCCAGAGTAAAGGTGCG, and the downstream branch Cx36 primer, TTCTGTTTCAGCGCTTAC-CAGTCC, with gel bands running at 326 base pairs for the wild-type allele and 215 base pairs for the Cx36 allele. Blood cell velocities from a total of 24 male mice (9 Cx36 ϩ/ϩ , 7 Cx36 ϩ/Ϫ , and 8 Cx36 Ϫ/Ϫ ) were measured in the experiments described here. Mice that did not survive imaging at least two different glucose levels, those that exhibited large involuntary movements during imaging, and those in which islets could not be located were eliminated from the data analysis. A total of 33 islets could be imaged in these animals, and all of these islets were included in the data analysis. At the conclusion of the image collection, the anesthetized mice were euthanized by cervical dislocation.
Catheterization. Catheters were surgically placed in the left common carotid artery and the right jugular vein as previously described (3) . The free ends of catheters were tunneled under the skin to the back of the neck, where they were exteriorized and sealed with stainless steel plugs. Lines were flushed the next day with 10 -50 l of saline containing 200 U/ml heparin and 5 mg/ml ampicillin (Sigma, St. Louis, MO). Animals were individually housed after surgery, and body weight was recorded. Mice were allowed to recover from surgery for 1 day and then used in imaging experiments within the next 4 days. During experiments, blood glucose levels were measured periodically at the artery catheter, using a Contour Blood Glucose Meter (Bayer HealthCare, Mishawaka, IN). Blood glucose levels were controlled by introducing human insulin (Novo Nordisk, Princeton, NJ) and/or 50% dextrose (Hospira, Lake Forest, IL) through the vein catheter. The flow of the insulin and dextrose was controlled separately with two syringe pumps (Harvard Aparatus, Holliston, MA).
Pancreas exteriorization. An intraperitoneal injection of xylazineketamine (20/80 mg/kg) was used to anesthetize the mice, and an incision in the abdominal cavity revealed the splenic end of the pancreas. Gauze bedding was placed on the abdominal cavity, and the pancreas-spleen connection was fixed over the bedding. The mouse was secured prone on a heated stage, and the pancreas in contact with the imaging cover slip. The exposed pancreas was kept moist during imaging by occasionally adding 0.9% saline to the gauze bedding.
In vivo fluorescence imaging. Imaging was performed using islets with GFP-labeled ␤-cells, tetramethylrhodamine dextran-labeled vasculature, and Alexa Fluor 647-labeled red blood cells (RBCs). The tetramethylrhodamine dextran tracer (2 ϫ 10 6 mol wt; Molecular Probes, Eugene, OR) was dissolved to 10 mg/ml in 0.9% saline. RBCs from a donor mouse were labeled by osmotic shock loading with Alexa Fluor 647 hydrazide tris(triethylammonium) salt (Molecular Probes) on the day of imaging. Briefly, 200 l of washed RBCs in 0.9% saline were added to a mixture of 35 l Alexa Fluor 647 (2 mg/ml in distilled deionized water) and 200 l of distilled deionized water, in a 0.5-ml Eppendorf tube. This was gently mixed by suction using a 200-l Eppendorf pipet and allowed to incubate at room temperature for 20 min. After incubation, 31.9 l of 10ϫ GIBCO PBS (Invitrogen, Carlsbad, CA) was added to the mixture to reanneal the RBCs, the tube was gently vortexed, and the contents were spun down for 4 min at 2,000 rpm (400 g) in an Eppendorf microfuge. The supernatant was drawn off, and the labeled RBCs were subsequently washed five times with 0.9% saline, each time spinning down for 3 min at 2,000 rpm (400 g). The resulting uniformly labeled RBCs solution was adjusted to 200 l with 0.9% saline and stored at 4°C. Before the imaging experiment both the vasculature label and the labeled RBCs were equilibrated to room temperature. During the imaging experiment a one-to-one mixture of vasculature label and labeled RBCs (ϳ50 l each) was injected in the mouse through a carotid artery catheter.
With the use of epifluorescence, islets in the exposed pancreas were identified by their GFP-labeled ␤-cells. GFP was excited at 488 nm, and islets were identified by the very bright red-edge emission through the 540-to 625-nm bandpass filter. For two-color high-speed imaging, an LSM 5 LIVE (Carl Zeiss, Jena, Germany) line-scanning confocal microscope with a ϫ20/0.8 NA planapochromat air objective lens was used. The tetramethylrhodamine dextran-labeled vasculature was excited using 532 nm, the Alexa Fluor 647-labeled RBCs were excited using 635 nm, and the emission was collected using 540-to 625-nm bandpass and 650-nm long-pass filters, respectively. There was no GFP excitation with the 532-nm laser. Vasculature and RBC emissions were collected simultaneously by two detection channels. The slit apertures were set at 3.20 Airy units for the vasculature channel and 2.78 Airy units for the RBC channel, yielding ϳ6 m imaging depth resolution. Time series scans were collected at 100 frames per second for either 30 s or 2 min. The frame size was 512 ϫ 256 pixels. For each pancreatic islet, time series scans were collected at three or more depths below the top surface of the islet. For each mouse, the number of islets available for study is limited by islet locations, and for most animals only a single islet could be located in the useful imaging range. However, during the imaging time window, up to three islets could be imaged while cycling one or more times between hyperglycemic and hypoglycemic blood glucose levels. The time stacks capture blood cell velocity dynamics in the midst of respiratory and heart-induced movements. We have recently developed an algorithm to correct the time stacks for this motion (30) . However, the analysis here is limited to scans for which the transverse movement was Ͻ5 m, which corresponds to the approximate diameter of many of the imaged capillaries. Data collection in the exocrine pancreas was made by imaging a nearby non-islet-containing region during periods between islet scans.
Data analysis. Image J (version 1.46h or newer) and the plug-ins available in the Image J hybrid, Fiji (available at http://fiji.sc/wiki/ index.php/Fiji) were used for much of the analysis. To determine if the calculated average velocity differences varied significantly from one another, an ANOVA test was performed. Specific pairwise significant changes in the average velocity differences between genotypes were then determined using the Tukey-Kramer test, and reported by the probability parameter, ␣.
Blood cell velocity analysis. The two-channel scans of the vascular label and the blood cell label were digitally separated into two files. To eliminate immobile background, the first frame was digitally subtracted from all subsequent frames. The blood cell data files of 3,000 or 12,000 frames were brightness/contrast equalized to give an overall single frame brightness histogram with an average of about 60/256 (8 bit). These images were threshold adjusted to visualize individual blood cells. Regions of interest encompassing islet or exocrine pancreas areas were chosen and separated from the main file. The labeled RBCs were further enhanced using "find edges," the brightness was maximized, and the threshold was adjusted using only "calculate threshold for each image." Image files thus processed resulted in frames with well-defined "blood cells" on a clean background (see Fig. 1A , shown in inverse contrast). The Image J plug-in MTrack2 was used to determine the frame-by-frame position of each labeled RBC in a time scan. Only RBCs that were present in at least three consecutive frames were tracked. We found the minimal number of tracking artifacts using the following settings: minimum object size (pixels) ϭ 25, maximum object size ϭ 300, maximum velocity ϭ 20, minimum track length (frames) ϭ 3. Velocities were determined by dividing the track length by the number of frames in which the labeled RBC was present and converting the resulting values in pixels per second to micrometer per second. During several imaging experiments one to a few labeled RBCs would sometimes become "stuck" in the imaging field of the islet and would remain so even with changes in glycemic conditions. These RBCs were excluded from any further analysis. Also, during the tracking analysis of several scans, the numerical labels on small numbers of labeled RBCs would switch between different cells. It was determined that these two artifacts could both be characterized by unusually large values of the length of track divided by the distance traveled, values both available in the MTrack2 output. By eliminating the small number of labeled cells with values of length of track/distance traveled Ͼ4.0, these artifacts were essentially eliminated. The velocities of the labeled cells from each scan were then used to determine velocity distributions and average velocities.
RESULTS

Tracking labeled RBCs to determine velocities.
The paths of fluorescently labeled RBCs in the islet vasculature can be tracked using the image J plug-in, MTrack2. Figure 1A shows a sequence of four frames from a typical 30-s scan with the RBCs labeled. Total labeled blood cell movements after 0.03 and 10.00 s are shown in Fig. 1 , B and C, respectively. Figure  1D shows the 10-s total movement overlaid on the tetramethylrhodamine dextran channel of the islet vasculature. The overlay shows that the MTrack2-determined velocity traces follow the vessel structure as expected. This supports the accuracy of the two-dimensional velocity distributions calculated from these scans.
Blood cell velocities vary within the islet. Because of variations in capillary sizes and lengths, we expect a distribution around an average velocity. Figure 2 shows velocity distributions from 30-s scans of islets from Cx36 ϩ/ϩ and Cx36
mice. For the Cx36 ϩ/ϩ mouse hyperglycemic (404 mg/dl glucose) and hypoglycemic (50 mg/dl glucose) conditions are shown. For the Cx36 Ϫ/Ϫ mouse the glucose concentrations are 318 and 50 mg/dl for hyperglycemic and hypoglycemic conditions, respectively. The velocity distributions shown are typical for our imaging experiments and suggest that islet blood cell velocities have a normal type distribution with a peak near the average value. There is little apparent shift in the average of the distribution for the Cx36 Ϫ/Ϫ mouse. This is consistent with previous observations from our lab that there are not significant differences in plasma insulin levels between Cx36 ϩ/ϩ and Cx36 Ϫ/Ϫ mice, at either high or low blood glucose levels (18) .
We also examined whether, at given blood glucose levels, differences in the measured average velocity existed between different regions of an islet. Figure 3 shows an example from a Cx36 Ϫ/Ϫ mouse in which large intraislet velocity differences at a constant blood glucose level are observed. The two imaging layers, which are 20 m apart, show, respectively, a slight rise and a slight fall in blood cell velocity with a change from hyperglycemic to hypoglycemic conditions. However, the velocity ranges between the two layers are quite different, being 695-770 m/s for layer 1 and 590 -525 m/s for layer 2. Given these intraislet velocity differences at a constant glucose level, we used velocities averaged over multiple scanned layers in the same islet during data analysis.
In addition to these intraislet variations in blood cell velocities, we have also observed significant variations in average blood cell velocities between different mice. These variations occur regardless of Cx36 genotype, with no significant difference in the average velocity between genotypes being observed. Therefore, in the final analysis presented here (see Fig.  5 ), we have used blood cell velocity differences rather than absolute blood cell velocities. Analyzing blood cell velocity differences removes mouse-to-mouse and islet-to-islet variations that are present with absolute blood cell velocities. In our experiments, the absolute values of blood cell velocities vary widely across the mice and islets measured, and we found no significant deviations in the average velocity values under lowor high-glucose conditions (data not shown). In contrast, the velocity differences are robust and reproducible, and thus allow behavioral variations between genotypes and glycemic levels to be measured. Measurement of velocity differences in a single animal under various conditions is not possible in bead flow experiments (24, 25) and is thus a major advantage of our live animal blood flow imaging approach.
Blood cell velocity behavior depends on Cx36 gap junctions. Figure 4 shows average blood cell velocity and blood glucose levels vs. time for representative islets in Cx36 ϩ/ϩ , Cx36 ϩ/Ϫ , and Cx36
Ϫ/Ϫ mice. For the wild-type mouse shown, the blood glucose is cycled two times from hyperglycemia to hypoglycemia. The average islet blood cell velocity follows these changes, being faster with hyperglycemic conditions and slower with hypoglycemic conditions, in agreement with previous reports (25, 42) . For the Cx36 ϩ/Ϫ and Cx36 Ϫ/Ϫ mice shown, blood glucose is cycled from hyperglycemia to hypoglycemia, and back to hyperglycemia. For the Cx36 ϩ/Ϫ mouse, the average blood cell velocity drops only slightly under hypoglycemic conditions. In the Cx36 Ϫ/Ϫ mouse, the average blood cell velocity remains essentially unchanged with changes in blood glucose levels. . Typical labeled blood cell velocity distributions. The velocity distributions from 30-s imaging scans are shown for the same islet at identical imaging depths under both hyperglycemic (Ͼ300 mg/dl glucose) and hypoglycemic (50 mg/dl glucose) conditions for both a Cx36 ϩ/ϩ islet and a Cx36 Ϫ/Ϫ islet where Cx36 is connexin 36. For the Cx36 ϩ/ϩ islet, the apparent mean of the distribution is shifted to a lower value under hypoglycemic conditions. For the Cx36
Velocity difference between hyperglycemia and hypoglycemia. Figure 5A shows the change in average islet blood cell velocity differences between hyperglycemic and hypoglycemic levels for all wild-type (n ϭ 9 mice, 13 islets), Cx36 ϩ/Ϫ (n ϭ 7 mice, 9 islets), and Cx36 Ϫ/Ϫ (n ϭ 8 mice, 11 islets) mice examined in this study. The average velocity difference of the labeled RBCs is substantially reduced when gap junction channels between ␤-cells are eliminated. One-way ANOVA shows significant differences between the three groups (Cx36 ϩ/ϩ , Cx36 ϩ/Ϫ , and Cx36 ϩ/Ϫ ) with F ϭ 5.1184, F crit ϭ 3.3158, and P value ϭ 0.0122. We used the Tukey-Kramer test to determine the significance of the pairwise differences. Fig. 5B . This comparison shows that there is little change in the velocity difference among the three different genotypes in the exocrine pancreas between hyperglycemia and hypoglycemia, and no statistical significance was found between the three groups.
DISCUSSION
We measured islet blood cell velocities in mice with reduced or absent gap junctions between their ␤-cells under both hyperglycemic and hypoglycemic conditions. In Cx36 Ϫ/Ϫ animals, and to a lesser extent in Cx36 ϩ/Ϫ animals, there is an apparent dysregulation of islet blood flow under hyperglycemic and hypoglycemic conditions (Fig. 5A) . The observed islet blood cell velocity response to glucose corresponds to the disruption in pulsatile insulin release that is seen in Cx36 Ϫ/Ϫ animals (18) where there are no gap junction connections between ␤-cells (9, 47) and also in type 2 diabetes (39, 40, 45, 46) . Whereas individual ␤-cells still exhibit calcium oscillations, they are not synchronous across the cells throughout the islet (5). In Cx36 Ϫ/Ϫ mice, this leads to a near abolition of first-phase insulin and a significant reduction in second-phase insulin pulses (18) . These animals are severely glucose intolerant, even though the total amount of insulin release is comparable to that of Cx36 ϩ/ϩ mice (18) . The reduction of coordinated calcium oscillations in Cx36 ϩ/Ϫ and Cx36
islets also correlates with the reduced change in the blood cell velocity difference upon glycemic changes observed in the islets of Cx36 ϩ/Ϫ and Cx36 Ϫ/Ϫ mice (Fig. 5A) . Combined, these data suggest that the coordinated pulsatile electrical activity mediated by the Cx36 channels is a key mechanism underlying the regulation of glucose-stimulated changes of intraislet blood cell velocities.
The changes in the blood cell velocity difference observed in response to changes in blood glucose levels are localized to the islet. That is, the glucose-dependent changes are observed only in the pancreatic islets and are essentially nonexistent in the pancreatic vasculature outside the islets (compare Fig. 5, A and  B) . Previously, it has been suggested that islet blood flow is controlled by the central nervous system. Specifically, cutting the vagus nerve to interrupt signals from the brain, or administering atropine to block muscarinic acetylcholine receptors, abolished increases in islet blood flow in rats following increases in blood glucose (24) . However, for the Cx36 Ϫ/Ϫ animals measured here, the blood cell velocity increases between hypoglycemia and hyperglycemia are only 38% of those observed in Cx36 ϩ/ϩ mice (Fig. 5A ). This suggests that control of islet blood flow is more dependent upon local electrical coupling between ␤-cells than global control by the central nervous system.
The mechanism by which electrical coupling of ␤-cells by Cx36 regulates islet blood flow likely involves signaling by direct electrical coupling or paracrine mediators. A direct electrical coupling model would require gap junctions between ␤-cells and intraislet neurons. This would seem to require the formation of a Cx36 homodimer, since Cx36 is unlikely to form a dimer with any other connexin (14) . It is not yet known if Cx36 is expressed in the intraislet nerves, although it is expressed in other peripheral neurons, particularly in the retina. There, Cx36 forms direct functional connections between ganglion cells and amacrine cells (44) . Cx36 expression is also present at the intersection of retinal rod and bipolar cells (43) . The other likely possibility is paracrine control of islet blood flow arising from products secreted from the islet cells. Three possible molecules that can control vasodilation (6, 10, 13, 15, 19, 21, 22, 27, 56) and are known to be associated with insulin secretion are nitric oxide (NO), ATP/adenosine, and dopamine (23, 31, 34, 48, 51, 54) . Because the control of islet blood velocity needs to occur upstream of the ␤-cells, paracrine control must also occur upstream. Although the possible mechanisms to control blood cell velocity by these potential paracrine mediators are not known, they are likely to have the following common characteristic. In Cx36 Ϫ/Ϫ mice, dysregulation of islet calcium dynamics (5) leads to reduced plasma insulin pulse amplitudes in vivo under a hyperglycemic clamp (18) . This suggests NO, ATP/adenosine, or dopamine would also be generated and released at reduced levels, which could lead to smaller hyperglycemic-induced increases in islet blood cell velocity in Cx36 ϩ/Ϫ and Cx36 Ϫ/Ϫ mice than in Cx36 ϩ/ϩ mice, as has been observed here (Fig. 5A) .
In our imaging studies, we observed that intraislet blood vessels are, with few exceptions, small-diameter capillaries. It is known that small-diameter capillaries often lack surrounding muscle cells and internal sphincters (26) that would act to control blood cell velocity. Thus, it is likely that control of islet blood flow occurs upstream, outside, or near the islet edge in the larger-diameter arterioles that feed the islet capillaries. This would require a mechanism that couples the electrical activity of the islet ␤-cells to these arterioles. Pancreatic islets are known to be highly innervated (32) , with nerves that follow islet blood vessels and in close juxtaposition to the islet cells (1) . Potentially, the islet ␤-cells could be directly coupled to intraislet nerve fibers electrically and/or by a paracrine mechanism to control islet blood cell velocity. Of course, local control is not the entire mechanism. As noted above, 38% of the normal blood cell velocity increase between hypoglycemic and hyperglycemic conditions is still measured in the Cx36
mice. This residual glucose-dependent velocity increase is due at least partially to central nervous system signaling (24) coupled with the potential paracrine signal from islet ␤-cells. Because the release of paracrine mediators likely corresponds to insulin secretion from the ␤-cells (23, 31, 34, 48, 51, 54) , we would expect differences in their temporal profile, although their total level may be unchanged as a function of Cx36 expression (18) . Such a paracrine signal(s) would putatively control local blood cell velocity via transmission to arterioles immediately adjacent to islets. A surprising thing about the islet blood cell velocity difference between hypoglycemic and hyperglycemic conditions for Cx36 ϩ/Ϫ mice is that it is not closer to midway between the velocity differences observed for Cx36 Ϫ/Ϫ and Cx36 ϩ/ϩ mice (Fig. 5A ). This is particularly true since, in isolated Cx36 ϩ/Ϫ islets, an average of 67% of islet cells display synchronized phase-locked calcium oscillations (5), signifying electrical coupling between ␤-cells. There are, however, characteristics of Cx36 ϩ/Ϫ islets, in addition to loss of electrical coupling, that could act to further reduce signaling, and thus average blood cell velocity. Previous studies of isolated Cx36 ϩ/Ϫ islets (5) have suggested that two distinct populations of these islets may exist. First, under hyperglycemic conditions there are mice with islets that still exhibit calcium wave propagation between coupled ␤-cells. However, the wave velocity was reduced by an average of 43% compared with Cx36 ϩ/ϩ islets. The reduced wave velocity would likely reduce the amplitude of an in vivo signal affecting islet blood cell velocity. A second population of Cx36 ϩ/Ϫ islets, from Ͼ40% of mice studied, showed synchronous phase-locked calcium oscillations in a portion of ␤-cells. However, calcium wave propagation was significantly disrupted, and more like the absence of calcium waves observed in Cx36 Ϫ/Ϫ islets (5). If Cx36 ϩ/Ϫ islets also exhibit disrupted calcium wave propagation in vivo, this could reduce signals controlling islet blood cell velocity. It is known that the amount of Cx36 in ␤-cells (2), as well as connexins in other tissues (7, 37, 53) , is reduced under extended hyperglycemic conditions. So, the observation of a smaller-than-expected glycemic-induced change of Cx36 ϩ/Ϫ islet blood cell velocity may have implications during the progression of diabetes. It would suggest that only a small loss in the number of Cx36 gap junction connections between ␤-cells could have a large effect on the regulation of islet blood cell velocity.
We have shown that reduced electrical coupling between islet ␤-cells, mediated by Cx36 gap junctions, leads to a concomitant decrease in the intraislet blood cell velocity difference between hypoglycemic and hyperglycemic conditions. This change is directly correlated with dysregulation of isolated islet calcium dynamics in Cx36 ϩ/Ϫ and Cx36 Ϫ/Ϫ islets (5) and reduced plasma insulin pulse amplitudes (17) . The glucose response in the Cx36 Ϫ/Ϫ mouse parallels many of the effects observed in type 2 diabetes (39, 40, 45, 46) , and it has recently been shown that the pancreatic islet vasculature can adapt to insulin resistance through vessel dilation and increased blood flow (11, 20) . Thus, gap junction-dependent changes in islet blood cell velocities as observed here may also play a role in the progression of diabetes.
